View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, May 18 (HealthDay News) -- Tympanometric manifestation of eustachian tube dysfunction (ETD) may not be normalized by treatment with intranasal aqueous triamcinolone acetonide (TAA-AQ), according to a study published in the May issue of the Archives of Otolaryngology -- Head & Neck Surgery.
Michael B. Gluth, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues investigated the efficacy of intranasal TAA-AQ in treating the tympanometric manifestations of ETD. Participants included 91 children and adults aged 6 years and older, presenting with otitis media with effusion, negative middle ear pressure, or both, between 2005 and 2008. Participants were randomized to receive either aqueous triamcinolone or matching placebo once daily intranasally for six weeks. The participants completed a symptom questionnaire and underwent tympanometry and otologic examination before and after treatment. Change in symptom scores (severity and frequency) and resolution of abnormal tympanometry were the main outcomes studied.
The investigators found there was no statistically significant difference between the triamcinolone and placebo group in normalization of abnormal tympanometric signs on either a per-patient basis or a per-ear basis. After adjusting for pre-study overall symptom score, there was no significant difference in the overall post-study symptom score between the two groups.
"Topical intranasal application of TAA-AQ did not increase the likelihood of normalization of the tympanometric manifestations of ETD at six weeks in a study group of subjects aged 6 years or older. On the basis of responses to a pretreatment and post-treatment questionnaire, it also appears unlikely to improve ETD-related symptom complaints," the authors write.
Funding for this study was provided by sanofi-aventis, U.S.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top